MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Other Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Other non-current liabilities remains negative
Q3 FY2026 other non-current liabilities was $0, compared with $7K a year earlier. Over 3 fiscal years it compounded at -97.1% a year.
Context
- Other non-current liabilities amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Other non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2K USD
- Year-over-year change
- -95.2%
- 3-year CAGR
- -97.1%
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2K | -95.2% |
| FY2024 | 2024-12-31 | 42K | -100.0% |
| FY2023 | 2023-12-31 | 152.55M | +81.7% |
| FY2022 | 2022-12-31 | 83.95M | — |
Other Non-current Liabilities vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 5, against a peer median of +318.6%.
- Other non-current liabilities amounts to 0.0% of total assets for MBX, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.35M USD | +4644.5% | +107.2% | 58.5% | |
| Sep 2026 | $87.92M USD | -15.0% | +9.4% | 19.8% | |
| Mar 2026 | $18.37M USD | — | — | 39.6% | |
| Mar 2026 | $4.59M USD | +15.9% | +4.4% | 1.4% | |
| Mar 2026 | $238K USD | +621.2% | +56.4% | 0.1% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $135K USD | — | — | 0.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $0 USD | -100.0% | -97.1% | 0.0% |
| Sep 2026 | €0 EUR | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding MBX) | — | +318.6% | +32.9% | 0.7% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.